A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
← catalyst calendarNCT06807268 · readout in 256 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
150estimated
Sites
43
Countries
China, Germany, Hungary +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-24 | actual | When the study began enrolling |
| Primary completion | 2027-05-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-02 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eczema
Interventions
- Drug: Abrocitinib — also filed as PF-04965842
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFResponse based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12
measured At week 12
Response based on achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI)-75 at Week 12
measured At week 12
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed